Davis, California, USA
April 18, 2018
Marrone Bio Innovations, Inc. (NASDAQ:MBII) (or "the Company"), a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets, today announced the pricing of its previously announced underwritten public offering. The Company is offering 7,275,000 registered shares of its common stock, par value $0.00001 per share, at a price to the public of $1.65 per share, resulting in gross proceeds of approximately $12 million. In connection with the offering, the Company has also granted the underwriter a 45-day option to purchase up to an additional 1,091,250 shares of common stock offered in the public offering to cover over-allotments, if any.
The Company intends to use the net proceeds from the offering primarily for general corporate purposes. The offering is expected to settle and close on April 20, 2018, subject to the satisfaction or waiver of customary closing conditions.
National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation (NasdaqCM:NHLD), is acting as sole book-running manager for the offering.
The securities described above are being offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-215024), including a base prospectus, previously filed with and declared effective by the Securities and Exchange Commission (SEC) on January 6, 2017. A preliminary prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and accompanying base prospectus may be obtained by contacting the book-running manager at the following address:
National Securities Corporation
200 Vesey Street, 25th Floor
New York, NY 10281
Attn: Marguerite Rogers
Telephone: 212-417-8227
Email: prospectusrequest@nationalsecurities.com
A final prospectus supplement describing the terms of the offering will be filed with the SEC. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of Marrone Bio Innovations, Inc., and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Topics
Species
